Business
Why did the Exopharm (ASX:EX1) share price surge 12% today?
The Exopharm Ltd (ASX: EX1) share price rocketed today after the company announced positive clinical trial results for its regenerative medical product, Plexaris.
At market close, the Exopharm share price is up by 12.93% today to 65 cents per share.
Exopharm is a biopharmaceutical company focused on developing regenerative medicine. It’s currently investigating the therapeutic potential of two products, Plexaris and Cevaris, in treating osteoarthritis.
The company was undergoing clinical trials to see if the medicine can restore arthritic cell tissue in rats. These clinical trials showed that the drugs had no adverse affects and were safe to trial on humans, however they also showed that drugs’ efficacy was limited to milder…
-
Business19 hours agoThis artificial intelligence (AI) and “Magnificent Seven” stock will be the next company to surpass a $3 trillion market cap by the end of 2025
-
General20 hours agoFootballers and movie stars: PM’s Shanghai tourism push
-
Business19 hours agoNvidia reaches the $4 trillion mark. Can it hit $5 trillion in 2025?
-
Noosa News19 hours agoYIMBYs vs NIMBYs as the battle for affordable housing moves into your backyard